Last updated: June 8, 2026
Pfizer Inc. v. Glenmark Pharmaceuticals Limited (1:19-cv-01209) Litigation Summary and Patent Analysis
Executive summary:
Pfizer v. Glenmark, 1:19-cv-01209, is a U.S. Hatch-Waxman patent infringement dispute filed in 2019. The case centers on Pfizer’s Orange Book-listed patents for a Pfizer-branded small-molecule drug and Glenmark’s planned generic launch, typically via ANDA and Paragraph IV certifications. The operative litigation posture turns on (1) which Pfizer patents are asserted, (2) Glenmark’s ANDA filing and Paragraph IV bases, and (3) whether the parties reached an effective settlement that triggers a permitted generic entry date.
However, a complete and accurate litigation summary and patent-specific analysis cannot be produced from the provided input alone. The docket number is not sufficient to identify the asserted patents, the asserted claims, claim constructions, key motions, the status of FDA exclusivities, or any settlement terms.
What patents were asserted in Pfizer v. Glenmark 1:19-cv-01209?
A litigation summary requires the list of asserted U.S. patents, their expiration dates, and the claims/issue(s) contested by the generic applicant. Those specifics are not contained in the provided information.
Which Pfizer Orange Book patents were at issue
Patent-at-issue analysis depends on the Orange Book record for the specific Pfizer drug tied to the docket. Without the drug identity and the Orange Book listing numbers/patent IDs, the asserted portfolio cannot be mapped.
How Glenmark’s Paragraph IV certification drove the claims
Claim and invalidity themes (noninfringement, obviousness, lack of enablement, written description, indefiniteness) depend on the Paragraph IV reasons stated in the ANDA certification and the asserted patent claims.
What is the procedural history of Pfizer v. Glenmark 1:19-cv-01209?
A correct timeline needs docket events such as the complaint date, answer, filing of motions to dismiss, Markman/hearing dates, summary judgment deadlines, and any trial date. None of these dates are provided.
Key docket milestones to summarize
A litigation summary normally enumerates:
- Complaint filing and asserted patents
- ANDA and Paragraph IV reference to FDA notice(s)
- Rule 12 and claim construction events
- Any stipulations, dismissals, or narrowing of asserted claims
- Final judgment or dismissal
- Any permanent injunction or entry-triggering terms
Without docket extracts, these cannot be reliably stated.
What did Pfizer allege in its complaint in 1:19-cv-01209?
Complaint-level analysis requires the infringement theory:
- direct infringement vs. induced infringement vs. contributory infringement
- method-of-use vs. composition claims
- product-specific design around or marketing-label theory
The input does not specify the complaint contents or the drug.
What invalidity arguments did Glenmark raise in 1:19-cv-01209?
Invalidity analysis requires identification of:
- prior art references used (patent docs, publications, non-patent literature)
- anticipation vs. obviousness frameworks
- enablement/written description issues and prosecution history estoppel
- indefiniteness and claim scope disputes
No such details are provided.
Was there a settlement or licensing agreement in Pfizer v. Glenmark 1:19-cv-01209?
Settlement analysis requires the terms that determine:
- whether the case was dismissed with or without prejudice
- the “trigger” mechanism for generic launch (entry date tied to patent expiry or exclusivity)
- whether a reserve/pre-launch inventory arrangement existed
- whether amendments to the ANDA were required
- any royalty or covenant-not-to-sue structure
These terms cannot be derived from docket number alone.
What is the Orange Book status and exclusivity exposure tied to this litigation?
Orange Book and exclusivity mapping requires:
- the specific marketed product name and dosage form
- patent numbers listed for the drug
- whether exclusivity was granted (NCE, 505(b)(2) exclusivity, pediatric exclusivity, 6-month forfeiture/extension dynamics)
- which patents are listed as expiring later than any settlement entry
No drug identity is supplied, so Orange Book status cannot be computed.
When would generic entry have been permitted based on patent expiry or settlement in 1:19-cv-01209?
Entry-date determination is a function of:
- earliest patent expiration among asserted patents
- any later expiring patents still asserted at the time of settlement/dismissal
- potential pediatric exclusivity extensions
- whether FDA 30-month stay was lifted or modified by settlement
No expiration data is provided.
How do you assess patent strength in this case given the claims at issue?
A patent-strength assessment depends on:
- claim scope and construction outcomes
- validity posture at dispositive stages
- outcomes of summary judgment or motion practice
- any inequitable conduct rulings (rare but material)
- whether the court found willful infringement exposure (affects leverage, damages)
No claim or decision data is provided.
What generic entry risks existed for Glenmark if the case went to judgment?
Generic entry risk analysis depends on:
- likelihood of injunction
- remaining barriers from other patents not asserted in the case
- whether design-around amendments could avoid infringement findings
- whether other litigations or PTAB outcomes affected enforceability
No asserted portfolio is provided.
Key Takeaways
- A docket number alone is insufficient to produce a complete, accurate litigation summary and patent analysis for Pfizer Inc. v. Glenmark Pharmaceuticals Limited (1:19-cv-01209).
- A correct summary requires the identified Pfizer drug, the asserted patent numbers, procedural milestones, and final disposition or settlement terms, none of which are present in the input.
- Any attempt to state asserted patents, expiration dates, or settlement entry triggers without docket-specific and drug-specific sourcing risks material error.
FAQs
- Which Pfizer Orange Book patents are commonly asserted in Paragraph IV cases like 1:19-cv-01209 for Glenmark?
- How does a Paragraph IV certification typically affect the 30-month FDA stay in Hatch-Waxman litigation?
- What court rulings most often shape outcomes in ANDA patent cases (Markman, claim construction, summary judgment)?
- How do settlement dismissals alter the FDA launch timeline compared with a final infringement judgment?
- What patent-expiration scenarios most frequently drive “design-around” strategy in generic litigation?
References (APA)
No sources were provided in the input.
